Aromatic Ring Compounds for Biomarker-Selective Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors lack precision due to tumor heterogeneity, often leading to delayed treatment and ineffective drug administration, necessitating the development of drugs that can provide targeted therapy based on molecular-level differences in tumors.
Innovation Solution
A compound with specific structural characteristics, such as aromatic ring compounds, is developed to target tumors with low expression or activity of mitochondria permeability transition pores, peptidyl-prolyl cis-trans isomerase F, NNMT gene, high DNA methylase expression, and high methylation levels of NNMT gene sites, providing precise treatment options.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the same treatment method or medication is used for all tumors based on source or pathological characteristic, then the treatment approach is simple and unified, but the treatment precision is low and valuable treatment time is delayed
Solution Approach 1:
The patent applies local quality by developing compounds with specific molecular structures that selectively target tumors based on their unique molecular characteristics. Different compounds are designed to interact with specific molecular markers (such as NNMT, UHRF1, DNA methylase) that are present in different tumor types, allowing precise differentiation and treatment of various tumor molecular subtypes rather than using a uniform treatment approach
2Reliability
If high dose of drug is administered to ensure treatment effect, then the treatment efficacy is improved, but the toxic side effects increase
Solution Approach 1:
The patent uses specific molecular markers as intermediaries to mediate the interaction between the drug and tumor cells. The compounds are designed to selectively bind to these molecular markers (NNMT, UHRF1, DNA methylase) that are overexpressed or mutated in tumors, allowing the drug to specifically target cancer cells while sparing normal cells, thereby maintaining high treatment efficacy with reduced toxic side effects
Data Source
AI summary
The present invention relates to an aromatic ring compound and use thereof. Specifically provided is a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof. The compound has a significantly excellent therapeutic effect on tumors with low expression, no expression, low activity or no activity of mitochondrial permeability transition pores; low expression, no expression, low activity or no activity of peptidyl-prolyl isomerase F; low expression or no expression of the NNMT gene; high expression of DNA methylases; high expression of UHRFl; high levels of methylation of nucleotide sites in the NNM′T gene; and/or high levels of methylation of DNA CpG sites in the NNMT gene region.